XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.33

-1.9%

Dec 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tharos who wrote (8225)	1/7/1999 10:27:00 AM
From: aknahow	Read Replies (2) of 17367

Open question, what do you think is best for XOMA shareholders? XXXXX In April 1996, as part of its long-term partnering strategy, Genentech entered into a collaboration agreement with XOMA to develop Genentech's hu1124 molecule through Phase II. This part of the collaboration is now complete, and based on the Phase II results Genentech will decide early in 1999 whether to continue the product collaboration with XOMA or itself continue with Phase III development. XOMA may decide whether to receive payments from Genentech when the molecule is commercialized or participate with Genentech in profit-sharing from the ultimate sales of the product. XXXXXXX Genentech's mention of the need to decide to continue with XOMA means they have thought about taking it back in house. What will Genentech decide and why and is this good or bad for XOMA? Xoma can decide on payment (s) when commercialized. (STRANGE THEY DID NOT USE IF) Or profit sharing from the ultimate sales. Of course we do not know how profits would be shared but profit sharing sounds better than royalties on gross sales, but it might not be. O.K. in the absence of facts, which has never stopped, most of us before, what's best?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next